Elevated P75NTR Expression Causes Death of Engrailed-deficient Midbrain Dopaminergic Neurons by Erk1/2 Suppression

Overview

Journal Neural Dev

Publisher Biomed Central

Specialty Neurology

Date 2009 Mar 18

PMID 19291307

Citations 21

Authors

Kambiz N Alavian

Paola Sgado

Lavinia Alberi

Srinivasa Subramaniam

Horst H Simon

Affiliations

Soon will be listed here.

Abstract

Background: The homeodomain transcription factors Engrailed-1 and Engrailed-2 are required for the survival of mesencephalic dopaminergic (mesDA) neurons in a cell-autonomous and gene-dose-dependent manner. Homozygote mutant mice, deficient of both genes (En1-/-;En2-/-), die at birth and exhibit a loss of all mesDA neurons by mid-gestation. In heterozygote animals (En1+/-;En2-/-), which are viable and fertile, postnatal maintenance of the nigrostriatal dopaminergic system is afflicted, leading to a progressive degeneration specific to this subpopulation and Parkinson's disease-like molecular and behavioral deficits.

Results: In this work, we show that the dose of Engrailed is inversely correlated to the expression level of the pan-neurotrophin receptor gene P75NTR (Ngfr). Loss of mesDA neurons in the Engrailed-null mutant embryos is caused by elevated expression of this neurotrophin receptor: Unusually, in this case, the cell death signal of P75NTR is mediated by suppression of Erk1/2 (extracellular-signal-regulated kinase 1/2) activity. The reduction in expression of Engrailed, possibly related to the higher levels of P75NTR, also decreases mitochondrial stability. In particular, the dose of Engrailed determines the sensitivity to cell death induced by the classic Parkinson-model toxin MPTP and to inhibition of the anti-apoptotic members of the Bcl-2 family of proteins.

Conclusion: Our study links the survival function of the Engrailed genes in developing mesDA neurons to the regulation of P75NTR and the sensitivity of these neurons to mitochondrial insult. The similarities to the disease etiology in combination with the nigral phenotype of En1+/-;En2-/- mice suggests that haplotype variations in the Engrailed genes and/or P75NTR that alter their expression levels could, in part, determine susceptibility to Parkinson's disease.

Citing Articles

Genetic Analysis of Neurite Outgrowth Inhibitor-Associated Genes in Parkinson's Disease: A Cross-Sectional Cohort Study.

Huang X, Wang Y, Xiang Y, Zhao Y, Pan H, Liu Z CNS Neurosci Ther. 2024; 30(10):e70070.

PMID: 39354865 PMC: 11445604. DOI: 10.1111/cns.70070.

Unraveling the AKT/ERK cascade and its role in Parkinson disease.

Keshri P, Singh S Arch Toxicol. 2024; 98(10):3169-3190.

PMID: 39136731 DOI: 10.1007/s00204-024-03829-9.

Developmental pathways linked to the vulnerability of adult midbrain dopaminergic neurons to neurodegeneration.

Prakash N Front Mol Neurosci. 2023; 15:1071731.

PMID: 36618829 PMC: 9815185. DOI: 10.3389/fnmol.2022.1071731.

Spatial RNA Sequencing Identifies Robust Markers of Vulnerable and Resistant Human Midbrain Dopamine Neurons and Their Expression in Parkinson's Disease.

Aguila J, Cheng S, Kee N, Cao M, Wang M, Deng Q Front Mol Neurosci. 2021; 14:699562.

PMID: 34305528 PMC: 8297217. DOI: 10.3389/fnmol.2021.699562.

c-Jun N-terminal Kinase Mediates Ligand-independent p75 Signaling in Mesencephalic Cells Subjected to Oxidative Stress.

Kraemer B, Clements R, Escobedo C, Nelson K, Waugh C, Elliott A Neuroscience. 2020; 453:222-236.

PMID: 33253821 PMC: 8783671. DOI: 10.1016/j.neuroscience.2020.11.036.

References

Mocanu M, Baxter G, Yellon D . Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000; 130(2):197-200. PMC: 1572087. DOI: 10.1038/sj.bjp.0703336. View

Farrer M . Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006; 7(4):306-18. DOI: 10.1038/nrg1831. View

Volonte C, Angelastro J, Greene L . Association of protein kinases ERK1 and ERK2 with p75 nerve growth factor receptors. J Biol Chem. 1993; 268(28):21410-5. View

Girault J, Greengard P . The neurobiology of dopamine signaling. Arch Neurol. 2004; 61(5):641-4. DOI: 10.1001/archneur.61.5.641. View

Hoagland M, Hoagland E, Swanson H . The p53 inhibitor pifithrin-alpha is a potent agonist of the aryl hydrocarbon receptor. J Pharmacol Exp Ther. 2005; 314(2):603-10. DOI: 10.1124/jpet.105.084186. View

Schultz W . Getting formal with dopamine and reward. Neuron. 2002; 36(2):241-63. DOI: 10.1016/s0896-6273(02)00967-4. View

Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V . Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A. 2005; 102(52):19126-31. PMC: 1323177. DOI: 10.1073/pnas.0508215102. View

Strelau J, Sullivan A, Bottner M, Lingor P, Falkenstein E, Suter-Crazzolara C . Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J Neurosci. 2000; 20(23):8597-603. PMC: 6773071. View

Lorenzo H, Susin S, Penninger J, Kroemer G . Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ. 1999; 6(6):516-24. DOI: 10.1038/sj.cdd.4400527. View

10.

Liang Q, Liou A, Ding Y, Cao G, Xiao X, Perez R . 6-Hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression. J Neurosci Res. 2004; 77(5):747-61. DOI: 10.1002/jnr.20198. View

11.

Troy C, Friedman J, Friedman W . Mechanisms of p75-mediated death of hippocampal neurons. Role of caspases. J Biol Chem. 2002; 277(37):34295-302. DOI: 10.1074/jbc.M205167200. View

12.

Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

13.

Simon H, SAUERESSIG H, Wurst W, Goulding M, OLeary D . Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci. 2001; 21(9):3126-34. PMC: 6762576. View

14.

Wang W, Shi L, Xie Y, Ma C, Li W, Su X . SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res. 2004; 48(2):195-202. DOI: 10.1016/j.neures.2003.10.012. View

15.

Tanaka K, Honda M, Takabatake T . Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol. 2004; 31(5-6):360-4. DOI: 10.1111/j.1440-1681.2004.04010.x. View

16.

Schober A . Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004; 318(1):215-24. DOI: 10.1007/s00441-004-0938-y. View

17.

Thuret S, Bhatt L, OLeary D, Simon H . Identification and developmental analysis of genes expressed by dopaminergic neurons of the substantia nigra pars compacta. Mol Cell Neurosci. 2004; 25(3):394-405. DOI: 10.1016/j.mcn.2003.11.004. View

18.

Wang X, Bauer J, Li Y, Shao Z, Zetoune F, Cattaneo E . Characterization of a p75(NTR) apoptotic signaling pathway using a novel cellular model. J Biol Chem. 2001; 276(36):33812-20. DOI: 10.1074/jbc.M010548200. View

19.

Li P, Nijhawan D, Budihardjo I, Srinivasula S, Ahmad M, Alnemri E . Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997; 91(4):479-89. DOI: 10.1016/s0092-8674(00)80434-1. View

20.

Chan S, Lee M, Tan K, Yang L, Lee A, Flotow H . Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem. 2003; 278(23):20453-6. DOI: 10.1074/jbc.C300138200. View